var data={"title":"Cimetidine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cimetidine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5902?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cimetidine-drug-information\" class=\"drug drug_general\">see &quot;Cimetidine: Drug information&quot;</a> and <a href=\"topic.htm?path=cimetidine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cimetidine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151515\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cimetidine Acid Reducer [OTC];</li>\n      <li>Tagamet HB [OTC] [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151516\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Cimetidine;</li>\n      <li>Dom-Cimetidine;</li>\n      <li>Mylan-Cimetidine;</li>\n      <li>Novo-Cimetidine;</li>\n      <li>Nu-Cimet;</li>\n      <li>PMS-Cimetidine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057349\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Histamine H<sub>2</sub> Antagonist</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442255\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Use has been replaced by other agents with a more favorable drug interaction profile. Consider judicial use in neonatal population due to an association of H<sub>2</sub> blocker use (ranitidine) and an increased incidence of NEC in VLBW neonates (Guillet 2006) and a reported approximate sixfold increase in mortality, NEC, and infection (ie, sepsis, pneumonia, UTI) in VLBW neonates receiving ranitidine (Terrin 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastroesophageal reflux:</b> Limited data available: Oral: 5 to 10 mg/kg/day in divided doses every 6 to 12 hours (Avery 1994; Chhattriwalla 1980; Nelson 1996); higher doses of 20 mg/kg/day have also been described (Avery 1994, Vandenplas 1987)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057342\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cimetidine-drug-information\" class=\"drug drug_general\">see &quot;Cimetidine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastroesophageal reflux disease (GERD):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents &lt;16 years: Limited data available: Oral: 20 to 40 mg/kg/day in 3 to 4 divided doses; maximum dose: 400 mg/dose (Cucchiara 1984; Cucchiara 1989; Lightdale 2013; NASPGHAN/ESPGHAN [Vandenplas 2009]). A pharmacokinetic modeling study suggests that the optimal dose for acid suppression is 10 mg/kg/dose every 6 hours and that some patients may need doses as high as 15 mg/kg/dose (Lambert 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;16 years: Oral: 400 mg 4 times daily or 800 mg twice daily for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Duodenal ulcer, treatment and maintenance:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;5 years and Adolescents &lt;16 years: Limited data available, efficacy results variable: Oral: 20 to 40 mg/kg/day in 3 to 4 divided doses for 4 to 8 weeks, followed by 5 to 8 mg/kg/dose once daily at bedtime (Chiang 1989; Thomson 1983). In the largest trail, 33 patients (ages 8 to 15 years) with duodenal ulcer were allocated to receive cimetidine 20 mg/kg/day (n=8), an antacid (n=12), or sucralfate (n=17) for 8 weeks followed by maintenance therapy with once daily bedtime doses of cimetidine 5 mg/kg/dose, antacid, or sucralfate. Short-term improvement occurred in all three groups with no significant difference (Chiang 1989).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;16 years: Oral: 300 mg 4 times daily or 800 mg at bedtime or 400 mg twice daily for up to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Duodenal ulcer, prophylaxis:</b> Adolescents &ge;16 years: Oral: 400 mg at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastric ulcer, active:</b> Adolescents &ge;16 years: Oral: 300 mg 4 times daily or 800 mg at bedtime for up to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome):</b> Adolescents &ge;16 years: Oral: 300 mg 4 times daily; adjust dose to patient response; maximum daily dose: 2,400 mg<b>/day </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sour stomach/Heartburn (OTC labeling):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prevention:</i> Children &ge;12 years and Adolescents: Oral: 200 mg daily up to 30 minutes prior to eating foods or beverages that cause heartburn (maximum daily dose: 400 mg/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Relief of symptoms:</i> Children &ge;12 years and Adolescents: Oral: 200 mg daily; maximum daily dose: 400 mg/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Duodenal ulcer, active:</b> Oral: 300 mg 4 times daily or 800 mg at bedtime or 400 mg twice daily for up to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Higher doses of 1,600 mg at bedtime for 4 weeks may be beneficial for a subpopulation of patients with larger duodenal ulcers (&gt;1 cm defined endoscopically) who are also heavy smokers (&ge;1 pack/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Duodenal ulcer, prophylaxis:</b> Oral: 400 mg at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastric ulcer, active:</b> Oral: 300 mg 4 times daily or 800 mg at bedtime for up to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastroesophageal reflux disease:</b> Oral: 400 mg 4 times daily or 800 mg twice daily for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pathological hypersecretory conditions:</b> Oral: 300 mg 4 times daily; adjust dose to patient response; maximum 2.4 g/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heartburn (OTC labeling):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prevention:</i> Oral: 200 mg daily up to 30 minutes prior to eating foods or beverages that cause heartburn (maximum: 400 mg/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Relief of symptoms:</i> Oral: 200 mg daily; maximum: 400 mg/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Adolescents &ge;16 years and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mild to moderate renal impairment:</i> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Severe renal impairment:</i> 300 mg every 12 hours; may increase frequency with caution. When hepatic impairment is also present, further reductions in dosage may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate recommendations: Adults (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>GFR &gt;50 mL/minute:</i> No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>GFR 10 to 50 mL/minute:</i> Administer 50% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>GFR &lt;10 mL/minute:</i> 300 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hemodialysis:</i> Dose after dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CCRT:</i> Administer 50% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Peritoneal dialysis:</i> 300 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adolescents &ge;16 years and Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution. Dosage adjustments may be needed in patients with both renal and hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151488\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg/5 mL (237 mL, 240 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cimetidine Acid Reducer: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tagamet HB: 200 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg, 300 mg, 400 mg, 800 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151472\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057353\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with food; do not administer simultaneously with antacids</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151508\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at room temperature. Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057352\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Short-term and maintenance treatment of duodenal ulcers; short-term treatment of benign gastric ulcers; treatment of gastroesophageal reflux disease (GERD); treatment of pathologic hypersecretory conditions (eg, Zollinger-Ellison syndrome) (All indications: FDA approved in ages &ge;16 years and adults); relief of heartburn associated with acid indigestion and sour stomach (OTC product: FDA approved in ages &ge;12 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151577\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cimetidine may be confused with simethicone</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151574\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrioventricular block, bradycardia, hypotension, tachycardia, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, confusion, decreased sexual activity, dizziness, drowsiness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, erythema multiforme, exfoliative dermatitis, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Gynecomastia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea, pancreatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Breast swelling</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, hemolytic anemia (immune-based), neutropenia, pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic fibrosis (case report), increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia, polymyositis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine, interstitial nephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pneumonia (causal relationship not established)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151495\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to cimetidine or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication (OTC), do not use if trouble or pain when swallowing food, vomiting with blood, or bloody or black stools, allergic to cimetidine or other acid reducers. Do not use with other acid reducers.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for histamine H<sub>2</sub> antagonists is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151476\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Confusion: Rare cases of reversible confusion have been associated with cimetidine; usually elderly or severely ill patients, or in patients with renal or hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vitamin B<sub>12</sub> deficiency: Prolonged treatment (&ge;2 years) may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use caution in this age group due to risk of confusion and other CNS effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Immunocompromised patients: May have increased risk of hyperinfection of strongyloidiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Use of gastric acid inhibitors, including proton pump inhibitors and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients (Canani 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; OTC labeling: When used for self-medication (OTC), notify health care provider before use if any of the following are present: Frequent chest pain; frequent wheezing particularly with heartburn; nausea/vomiting; unexplained weight loss; stomach pain; heartburn &gt;3 months; heartburn with light-headedness, sweating, or dizziness; chest pain or shoulder pain with shortness of breath; sweating or pain that spreads to arms, neck, or shoulders; light-headedness. Stop use and notify health care provider if heartburn continues or worsens, stomach pain continues, or if use is required &gt;14 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855419\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use of gastric acid inhibitors, including proton pump inhibitors and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients (Canani 2006). A large epidemiological study has suggested an increased risk for developing pneumonia in patients receiving H<sub>2</sub> receptor antagonists; however, a causal relationship with cimetidine has not been demonstrated. A cohort analysis including over 11,000 neonates reported an association of H<sub>2</sub> blocker use and an increased incidence of NEC in VLBW neonates (Guillet 2006). An approximate sixfold increase in mortality, NEC, and infection (ie, sepsis, pneumonia, UTI) was reported in patients receiving another H<sub>2</sub> blocker, ranitidine, in a cohort analysis of 274 VLBW neonates (Terrin 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151562\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OAT3, OCT2, P-glycoprotein/ABCB1; <b>Inhibits</b> CYP1A2 (weak), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP2E1 (weak), CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151481\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13156&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Acalabrutinib.  Management: To minimize the potential for a significant interaction, separate administration of these agents by giving acalabrutinib 2 hours before ingestion of a histamine-2 receptor antagonist.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfentanil: Cimetidine may increase the serum concentration of Alfentanil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: Cimetidine may increase the serum concentration of Amiodarone.  Management: Consider alternatives to cimetidine. If this combination cannot be avoided, monitor for increased amiodarone concentrations/effects with cimetidine initiation/dose increase or decreased concentrations/effects with cimetidine discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: May enhance the adverse/toxic effect of Cimetidine. Specifically, there is a theoretical potential for enhanced effects on reducing endogenous steroid activity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Systemic): Cimetidine may increase the serum concentration of Azelastine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromazepam: Cimetidine may increase the serum concentration of Bromazepam.  Management: Consider use of bromazepam with an H2-antagonist that is not a potent CYP inhibitor (e.g., ranitidine) or alternatively, consider use of cimetidine with a benzodiazepine that does not undergo oxidative metabolism (e.g., lorazepam).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Cimetidine may increase the serum concentration of Calcium Channel Blockers.  Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.<b> Exceptions: </b>AmLODIPine; Clevidipine; NiCARdipine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: Cimetidine may increase serum concentrations of the active metabolite(s) of Capecitabine. Specifically, concentrations of fluorouracil may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Cimetidine may increase the serum concentration of CarBAMazepine. The serum carbamazepine concentration might return to normal within one week of starting cimetidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carmustine: Cimetidine may enhance the myelosuppressive effect of Carmustine.  Management: Consider alternatives to cimetidine in patients receiving carmustine.  If the combination cannot be avoided, monitor for enhanced carmustine myelotoxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: Cimetidine may increase the serum concentration of Carvedilol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefuroxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: Cimetidine may increase the serum concentration of Chlormethiazole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: Cimetidine may increase the serum concentration of Cisapride.  Management: Consider alternatives to cimetidine. If this combination cannot be avoided, monitor for toxic effects of cisapride if cimetidine is initiated/dose increased, or decreased efficacy if cimetidine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Cimetidine may increase the serum concentration of CloZAPine.  Management: Consider use of an alternative H2 antagonist. Monitor for increased toxic effects of clozapine if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dalfampridine: Cimetidine may increase the serum concentration of Dalfampridine.  Management: Recommendations differ significantly between international labelings in regards to the concomitant use of dalfampridine (referred to as fampridine in Canada) and cimetidine. Consult appropriate product labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Histamine H2 Receptor Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine.  The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Histamine H2 Receptor Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: Cimetidine may increase the serum concentration of Dofetilide. This is likely via inhibition of dofetilide renal tubular secretion (primarily) and inhibition of dofetilide metabolism. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Cimetidine may increase the serum concentration of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EpiRUBicin: Cimetidine may increase the serum concentration of EpiRUBicin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Escitalopram: Cimetidine may increase the serum concentration of Escitalopram.  Management: Consider using an alternative H<sub>2</sub>-antagonist to avoid the risk of escitalopram toxicity. Escitalopram Canadian product labeling recommends limiting escitalopram dose to 10 mg/day with concomitant use of cimetidine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floxuridine: Cimetidine may increase serum concentrations of the active metabolite(s) of Floxuridine. Specifically, concentrations of fluorouracil may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: Cimetidine may increase the serum concentration of Flunitrazepam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Systemic): Cimetidine may increase the serum concentration of Fluorouracil (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: Cimetidine may enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Cimetidine may increase the serum concentration of Fosphenytoin-Phenytoin.  Management: Consider using an alternative H<sub>2</sub>-antagonist to avoid this interaction. Monitor for toxic effects of hydantoin anticonvulsants if cimetidine is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or after administration of a histamine H2-antagonist, and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: Cimetidine may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, consider decreasing ibrutinib to 140 mg daily. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Histamine H2 Receptor Antagonists may decrease the absorption of Iron Salts. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Itraconazole.  Management: When this combination is used, the itraconazole should be administered with a non-diet cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Histamine H2 Receptor Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Ledipasvir. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mebendazole: Cimetidine may increase the serum concentration of Mebendazole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: Cimetidine may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meperidine: Cimetidine may increase the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Cimetidine may increase the serum concentration of MetFORMIN.  Management: Consider alternatives to cimetidine in patients receiving metformin due to a potential for increased metformin concentrations and toxicity (including lactic acidosis).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Histamine H2 Receptor Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: Cimetidine may increase the serum concentration of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moclobemide: Cimetidine may decrease the metabolism of Moclobemide.  Management: Consider using alternative agents to lower gastric pH in order to avoid this interaction. If combined, a moclobemide dose reduction of 50% is recommended and patients should be monitored for increased moclobemide effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Histamine H2 Receptor Antagonists may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be impaired by H2-antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Cimetidine may increase the serum concentration of Neratinib. Cimetidine may decrease the serum concentration of Neratinib. Specifically, cimetidine may reduce neratinib absorption.  Management: Avoid concomitant use of neratinib and cimetidine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicotine: Cimetidine may increase the serum concentration of Nicotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nilotinib.  Management: The nilotinib dose should be given 10 hours after or 2 hours before the H2 receptor antagonist in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: Histamine H2 Receptor Antagonists may decrease the serum concentration of PAZOPanib.  Management: Avoid the use of histamine H2-antagonists in combination with pazopanib.  Strategies to minimize the expected interaction between these agents (eg, dose separation) have not been investigated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: Cimetidine may increase the serum concentration of Pentoxifylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Perhexiline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pilsicainide: Cimetidine may increase the serum concentration of Pilsicainide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent use of oral suspension with H2-antagonists whenever possible. Monitor patients closely for decreased antifungal effects if this combination is used. Delayed-release posaconazole tablets may be less likely to interact.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: Cimetidine may increase the serum concentration of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Praziquantel: Cimetidine may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procainamide: Cimetidine may increase the serum concentration of Procainamide.  Management: Consider an alternative H2-receptor antagonist in patients taking procainamide. If combined, monitor for increased therapeutic effects/toxicity of procainamide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: Cimetidine may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Cimetidine may increase the serum concentration of QuiNIDine.  Management: Consider alternatives to cimetidine. If the combination cannot be avoided, monitor for increased quinidine concentrations/toxicity with cimetidine initiation/dose increase, or decreased concentrations/effects with cimetidine discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: Cimetidine may increase the serum concentration of QuiNINE. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Risedronate: Histamine H2 Receptor Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: Cimetidine may increase serum concentrations of the active metabolite(s) of Roflumilast. Cimetidine may increase the serum concentration of Roflumilast. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Histamine H2 Receptor Antagonists may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Histamine H2 Receptor Antagonists may diminish the diagnostic effect of Secretin. Specifically, use of H2-Antagonists may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of histamine H2-antagonists (H2RAs) and secretin. Discontinue H2RAs at least 2 days prior to secretin administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: Cimetidine may decrease the metabolism of Selective Serotonin Reuptake Inhibitors. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Cimetidine may increase the serum concentration of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: Cimetidine may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: Cimetidine may increase serum concentrations of the active metabolite(s) of Tegafur. Specifically, concentrations of fluorouracil may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Cimetidine may decrease the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Cimetidine may decrease the metabolism of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Histamine H2 Receptor Antagonists may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Velpatasvir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cimetidine may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zaleplon: Cimetidine may decrease the metabolism of Zaleplon. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ZOLMitriptan: Cimetidine may increase the serum concentration of ZOLMitriptan. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151511\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Prolonged treatment (&ge;2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151484\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3338825\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Cimetidine crosses the placenta (Howe 1981). Histamine H<sub>2</sub> antagonists have been evaluated for the treatment of gastroesophageal reflux disease (GERD), as well as gastric and duodenal ulcers during pregnancy (Cappell 2003; Richter 2003). Histamine H<sub>2</sub> antagonists may be used for aspiration prophylaxis prior to cesarean delivery (ASA 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057348\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, gastric pH, occult blood with GI bleeding; renal function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151475\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitive inhibition of histamine at H<sub>2</sub> receptors of the gastric parietal cells resulting in reduced gastric acid secretion, gastric volume and hydrogen ion concentration reduced</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151494\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 80% reduction in gastric acid secretion for 4 to 5 hours after 300 mg dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Children and Adolescents: 1.23 &plusmn; 0.45 L/kg (Lloyd 1985b); Adults: 1 to 1.5 L/kg (Somogyi 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 20% (Somogyi 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Partially hepatic, forms metabolites (Somogyi 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~60% to 70% (Somogyi 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Neonates: 3.6 hours (Lloyd 1985a); Children and Adolescents: 1.39 &plusmn; 0.25 hours (Lloyd 1985b); Adults: ~2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: 0.75 to 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily urine (48% as unchanged drug); feces (2%) (Somogyi 1983)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10806351\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Commercial oral solution is available (strength expressed as base: 60 mg/mL)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 60 mg/mL oral suspension may be made with tablets. Place twenty-four 300 mg tablets in 5 mL of sterile water for ~3-5 minutes to dissolve film coating. Crush tablets in a mortar and reduce to a fine powder. Add 10 mL of glycerin and mix to a uniform paste; mix while adding Simple Syrup, NF in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 17 days. </p>\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151497\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cimetidine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/5 mL (237 mL): $98.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cimetidine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $4.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $160.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $261.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (100): $501.69</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151498\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aci-Med (ZA);</li>\n      <li>Acidnor (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Aciloc (DK, FI);</li>\n      <li>Acinil (DK, SE);</li>\n      <li>Agocim (LK);</li>\n      <li>Alcatex (MX);</li>\n      <li>Altramet (HR, PL);</li>\n      <li>Apo-Cimetidine (NZ);</li>\n      <li>Belomet (HR);</li>\n      <li>Benomet (ID);</li>\n      <li>Biomag (IT);</li>\n      <li>Brumetidina (IT, VN);</li>\n      <li>Campanex (GR);</li>\n      <li>Cemedin 400 (IL);</li>\n      <li>Cementin (SG);</li>\n      <li>Cencamat (TH);</li>\n      <li>Cidine (TH);</li>\n      <li>Cigamet (TH);</li>\n      <li>Cimbene (BB, BM, BS, BZ, GY, JM, SR, TT);</li>\n      <li>Cimedine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Cimehexal (HU, LU);</li>\n      <li>Cimeldine (HU, IE);</li>\n      <li>Cimet (ET, TH);</li>\n      <li>Cimetag (AE, AT, BH, KW, QA);</li>\n      <li>Cimetase (MX);</li>\n      <li>Cimetid (BD);</li>\n      <li>Cimetidin (BG, CH, DE, NO);</li>\n      <li>Cimetidin AL (HU);</li>\n      <li>Cimetidina (CL, PY);</li>\n      <li>Cimetidine (CZ);</li>\n      <li>Cimetin (CZ, EC, IN);</li>\n      <li>Cimewell (TW);</li>\n      <li>Cimex (FI);</li>\n      <li>Cimexol (ID);</li>\n      <li>CimLich (LU);</li>\n      <li>Cimulcer (MY, PH);</li>\n      <li>Cinadine (ZA);</li>\n      <li>Cintag (BR);</li>\n      <li>Cismetin (KR);</li>\n      <li>Citidine (HK);</li>\n      <li>Citius (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Cytine (NZ);</li>\n      <li>Defense (TW);</li>\n      <li>Dispamet (AE, BH, CY, EG, IQ, IR, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Dyspamet (JO);</li>\n      <li>Ficimet (BD);</li>\n      <li>Gadol (VE);</li>\n      <li>Gastrodin (TW);</li>\n      <li>Gawei (TW);</li>\n      <li>Gerucim (HR);</li>\n      <li>Getidin (PH);</li>\n      <li>H-2 (KR);</li>\n      <li>H2 Blocker-ratiopharm (LU);</li>\n      <li>Haldin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Hexamet (ZA);</li>\n      <li>Himentin (SG);</li>\n      <li>Histodil (HN, HU, RU, VN);</li>\n      <li>Histodil[inj.] (HU);</li>\n      <li>Iwamet (TH);</li>\n      <li>Lenamet (ZA);</li>\n      <li>Lenamet OTC (ZA);</li>\n      <li>Lock 2 (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Magicul (AU);</li>\n      <li>Manomet (TH);</li>\n      <li>Neutronorm (AT);</li>\n      <li>Nuardin (BE, LU);</li>\n      <li>Nulcer (ID);</li>\n      <li>Piovalen (GR);</li>\n      <li>Powegon (TW);</li>\n      <li>Sanmetidin (ID);</li>\n      <li>Secapine (ZA);</li>\n      <li>Shintamet (MY, PH);</li>\n      <li>Siamidine (TH);</li>\n      <li>Simaglen (HK);</li>\n      <li>Stogamet (TW);</li>\n      <li>Stomedine (FR, TH);</li>\n      <li>Stomet (IT);</li>\n      <li>Tagamet (AE, BB, BF, BH, BJ, BM, BR, BS, BZ, CI, CN, CY, EG, ET, FR, GB, GH, GM, GN, GR, GY, IL, IQ, IR, IT, JM, JO, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, OM, PK, PT, QA, SA, SC, SD, SE, SG, SL, SN, SR, SY, TN, TT, TW, TZ, UG, VN, YE, ZM, ZW);</li>\n      <li>Tamex (LK);</li>\n      <li>Tenomet (TR);</li>\n      <li>Timet (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MT, OM, QA, SA, SY, YE);</li>\n      <li>Tobymet (ID);</li>\n      <li>Ulcedin (IT);</li>\n      <li>Ulcerfen (AR);</li>\n      <li>Ulcerid (BD);</li>\n      <li>Ulcerin (HK, ZW);</li>\n      <li>Ulcidine (MY);</li>\n      <li>Ulcim (ZA);</li>\n      <li>Ulcimet (EC, ID, PE, UY);</li>\n      <li>Ulcomedina (IT);</li>\n      <li>Ulcomet (EE);</li>\n      <li>Ulsikur (ID);</li>\n      <li>Ultipus (HK);</li>\n      <li>Weisdin (TW);</li>\n      <li>Wergen (TW);</li>\n      <li>Xepamet (ID, MY, SG)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Avery GB, Fletcher MA, MacDonald MG, eds. <i>Neontatology - Pathophysiology and Management of the Newborn</i>. 4th ed. Philadelphia, PA: Lippincott Company; 1994.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canani RB, Cirillo P, Roggero P, et al, &quot;Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,&quot; <i>Pediatrics</i>, 2006, 117(5):e817-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/16651285 /pubmed\" target=\"_blank\" id=\"16651285 \">16651285 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chhattriwalla Y, Colon AR, Scanlon JW. The use of cimetidine in the newborn. <i>Pediatrics</i>. 1980;65(2):301-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/7354975/pubmed\" target=\"_blank\" id=\"7354975\">7354975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chiang BL, Chang MH, Lin MI, Hsu JY, Wang CY, Wang TH. Chronic duodenal ulcer in children: clinical observation and response to treatment. <i>J Pediatr Gastroenterol Nutr</i>. 1989;8(2):161-165.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/2709247/pubmed\" target=\"_blank\" id=\"2709247\">2709247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cimetidine oral solution [prescribing information]. Amityville, NY: Hi-Tech Pharmacol Co., Inc; August 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cimetidine tablet [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals, Inc; January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cucchiara S, Gobio-Casali L, Balli F, et al. Cimetidine treatment of reflux esophagitis in children: an Italian multicentric study. <i>J Pediatr Gastroenterol Nutr</i>. 1989;8(2):150-156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/2651632/pubmed\" target=\"_blank\" id=\"2651632\">2651632</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cucchiara S, Staiano A, Romaniello G, Capobianco S, Auricchio S. Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis. <i>Arch Dis Child</i>. 1984;59(9):842-847.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/6385868/pubmed\" target=\"_blank\" id=\"6385868\">6385868</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guillet R, Stoll BJ, Cotten CM, et al, &quot;Association of H<sub>2</sub>-Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants,&quot; <i>Pediatrics</i>, 2006, 117(2):137-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/16390920/pubmed\" target=\"_blank\" id=\"16390920\">16390920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambert J, Mobassaleh M, and Grand RJ, &ldquo;Efficacy of Cimetidine for Gastric Acid Suppression in Pediatric Patients,&rdquo; <i>J Pediatr</i>, 1992, 120(3):474-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/1538302/pubmed\" target=\"_blank\" id=\"1538302\">1538302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lightdale JR, Gremse DA; Section on Gastroenterology, Hepatology, and Nutrition. Gastroesophageal reflux: management guidance for the pediatrician. <i>Pediatrics</i>. 2013;131(5):e1684-1695.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/23629618/pubmed\" target=\"_blank\" id=\"23629618\">23629618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lloyd CW, Martin WJ, Taylor BD, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Cimetidine and Metabolites in Critically Ill Children,&rdquo; <i>J Pediatr</i>, 1985, 107(2):295-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/4020559/pubmed\" target=\"_blank\" id=\"4020559\">4020559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lloyd CW, Martin WJ, and Taylor BD, &ldquo;The Pharmacokinetics of Cimetidine and Metabolites in a Neonate,&rdquo; <i>Drug Intell Clin Pharm</i>, 1985a, 19(3):203-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/3884305 /pubmed\" target=\"_blank\" id=\"3884305 \">3884305 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson WE, Behrman RE, Kliegman RM, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders Company; 1996.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Somogyi A and Gugler R, &ldquo;Clinical Pharmacokinetics of Cimetidine,&rdquo; <i>Clin Pharmacokinet</i>, 1983, 8(6):463-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/6418428 /pubmed\" target=\"_blank\" id=\"6418428 \">6418428 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terrin G, Passariello A, De Curtis M, et al, &quot;Ranitidine Is Associated With Infections, Necrotizing Enterocolitis, and Fatal Outcome in Newborns,&quot; <i>Pediatrics</i>, 2012, 129(1):40-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/22157140/pubmed\" target=\"_blank\" id=\"22157140\">22157140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomson RB, Attenburrow AA, Goel KM. Cimetidine in primary duodenal ulcer in children. <i>Scott Med J</i>. 1983;28(2):164-167.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/6867697/pubmed\" target=\"_blank\" id=\"6867697\">6867697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). <i>J Pediatr Gastroenterol Nutr</i>. 2009;49(4):498-547.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/19745761/pubmed\" target=\"_blank\" id=\"19745761\">19745761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vandenplas Y, Sacre L. The use of cimetidine in newborns. <i>Am J Perinatol</i>. 1987;4(2):131-133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cimetidine-pediatric-drug-information/abstract-text/3494461/pubmed\" target=\"_blank\" id=\"3494461\">3494461</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13156 Version 183.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F151515\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F151516\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057349\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442255\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1057342\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F151488\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F151472\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057353\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F151508\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057352\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F151577\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F151574\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F151495\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F151476\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855419\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F151562\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F151481\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F151511\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F151484\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3338825\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1057348\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F151475\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F151494\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10806351\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F151497\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F151498\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13156|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cimetidine-drug-information\" class=\"drug drug_general\">Cimetidine: Drug information</a></li><li><a href=\"topic.htm?path=cimetidine-patient-drug-information\" class=\"drug drug_patient\">Cimetidine: Patient drug information</a></li></ul></div></div>","javascript":null}